Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Membrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation.

Yang TH, St John LS, Garber HR, Kerros C, Ruisaard KE, Clise-Dwyer K, Alatrash G, Ma Q, Molldrem JJ.

J Immunol. 2018 Sep 1;201(5):1389-1399. doi: 10.4049/jimmunol.1800324. Epub 2018 Jul 18.

2.

Neuropilin-1 mediates neutrophil elastase uptake and cross-presentation in breast cancer cells.

Kerros C, Tripathi SC, Zha D, Mehrens JM, Sergeeva A, Philips AV, Qiao N, Peters HL, Katayama H, Sukhumalchandra P, Ruisaard KE, Perakis AA, St John LS, Lu S, Mittendorf EA, Clise-Dwyer K, Herrmann AC, Alatrash G, Toniatti C, Hanash SM, Ma Q, Molldrem JJ.

J Biol Chem. 2017 Jun 16;292(24):10295-10305. doi: 10.1074/jbc.M116.773051. Epub 2017 May 3.

3.

Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells.

Peters HL, Tripathi SC, Kerros C, Katayama H, Garber HR, St John LS, Federico L, Meraz IM, Roth JA, Sepesi B, Majidi M, Ruisaard K, Clise-Dwyer K, Roszik J, Gibbons DL, Heymach JV, Swisher SG, Bernatchez C, Alatrash G, Hanash S, Molldrem JJ.

Cancer Immunol Res. 2017 Apr;5(4):319-329. doi: 10.1158/2326-6066.CIR-16-0141. Epub 2017 Mar 2.

4.

PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.

Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, Kanodia S, Ruisaard KE, Giralt SA, Estey EH, Cortes J, Komanduri KV, Clise-Dwyer K, Alatrash G, Ma Q, Champlin RE, Molldrem JJ.

Leukemia. 2017 Mar;31(3):697-704. doi: 10.1038/leu.2016.254. Epub 2016 Sep 22.

5.

A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.

Ma Q, Garber HR, Lu S, He H, Tallis E, Ding X, Sergeeva A, Wood MS, Dotti G, Salvado B, Ruisaard K, Clise-Dwyer K, John LS, Rezvani K, Alatrash G, Shpall EJ, Molldrem JJ.

Cytotherapy. 2016 Aug;18(8):985-994. doi: 10.1016/j.jcyt.2016.05.001. Epub 2016 Jun 2.

6.

Activity of 8F4, a T-cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo.

Sergeeva A, He H, Ruisaard K, St John L, Alatrash G, Clise-Dwyer K, Li D, Patenia R, Hong R, Sukhumalchandra P, You MJ, Gagea M, Ma Q, Molldrem JJ.

Leukemia. 2016 Jul;30(7):1475-84. doi: 10.1038/leu.2016.57. Epub 2016 Mar 8.

7.

Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome.

Colla S, Ong DS, Ogoti Y, Marchesini M, Mistry NA, Clise-Dwyer K, Ang SA, Storti P, Viale A, Giuliani N, Ruisaard K, Ganan Gomez I, Bristow CA, Estecio M, Weksberg DC, Ho YW, Hu B, Genovese G, Pettazzoni P, Multani AS, Jiang S, Hua S, Ryan MC, Carugo A, Nezi L, Wei Y, Yang H, D'Anca M, Zhang L, Gaddis S, Gong T, Horner JW, Heffernan TP, Jones P, Cooper LJ, Liang H, Kantarjian H, Wang YA, Chin L, Bueso-Ramos C, Garcia-Manero G, DePinho RA.

Cancer Cell. 2015 May 11;27(5):644-57. doi: 10.1016/j.ccell.2015.04.007.

8.

Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model.

Jiang H, Clise-Dwyer K, Ruisaard KE, Fan X, Tian W, Gumin J, Lamfers ML, Kleijn A, Lang FF, Yung WK, Vence LM, Gomez-Manzano C, Fueyo J.

PLoS One. 2014 May 14;9(5):e97407. doi: 10.1371/journal.pone.0097407. eCollection 2014.

9.

A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia.

Zhang M, Sukhumalchandra P, Enyenihi AA, St John LS, Hunsucker SA, Mittendorf EA, Sergeeva A, Ruisaard K, Al-Atrache Z, Ropp PA, Jakher H, Rodriguez-Cruz T, Lizee G, Clise-Dwyer K, Lu S, Molldrem JJ, Glish GL, Armistead PM, Alatrash G.

Clin Cancer Res. 2013 Jan 1;19(1):247-57. doi: 10.1158/1078-0432.CCR-12-2753. Epub 2012 Nov 12.

10.

Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy.

Alatrash G, Mittendorf EA, Sergeeva A, Sukhumalchandra P, Qiao N, Zhang M, St John LS, Ruisaard K, Haugen CE, Al-Atrache Z, Jakher H, Philips AV, Ding X, Chen JQ, Wu Y, Patenia RS, Bernatchez C, Vence LM, Radvanyi LG, Hwu P, Clise-Dwyer K, Ma Q, Lu S, Molldrem JJ.

J Immunol. 2012 Dec 1;189(11):5476-84. doi: 10.4049/jimmunol.1201221. Epub 2012 Oct 26.

11.

Breast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anticancer adaptive immune response.

Mittendorf EA, Alatrash G, Qiao N, Wu Y, Sukhumalchandra P, St John LS, Philips AV, Xiao H, Zhang M, Ruisaard K, Clise-Dwyer K, Lu S, Molldrem JJ.

Cancer Res. 2012 Jul 1;72(13):3153-62. doi: 10.1158/0008-5472.CAN-11-4135. Epub 2012 May 7.

12.

The role of antigen cross-presentation from leukemia blasts on immunity to the leukemia-associated antigen PR1.

Alatrash G, Ono Y, Sergeeva A, Sukhumalchandra P, Zhang M, St John LS, Yang TH, Ruisaard K, Armistead PM, Mittendorf EA, He H, Qiao N, Rodriguez-Cruz T, Liang S, Clise-Dwyer K, Wieder ED, Lizee G, Lu S, Molldrem JJ.

J Immunother. 2012 May;35(4):309-20. doi: 10.1097/CJI.0b013e31824b3b14.

13.

An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells.

Sergeeva A, Alatrash G, He H, Ruisaard K, Lu S, Wygant J, McIntyre BW, Ma Q, Li D, St John L, Clise-Dwyer K, Molldrem JJ.

Blood. 2011 Apr 21;117(16):4262-72. doi: 10.1182/blood-2010-07-299248. Epub 2011 Feb 4.

Supplemental Content

Loading ...
Support Center